GlassScriptPhysician profile
James Kent Bailey
NPI 1699750349
$5,667.02
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,108 · 2020: $1,343 · 2021: $1,164 · 2022: $38.26 · 2024: $14.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $457.91 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $435.33 | 2019-2021 | |
| Amgen INC. | $390.77 | 2019-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $358.17 | 2019-2020 | |
| Novo Nordisk INC | $343.26 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.57 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $268.78 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.70 | 2019-2021 | |
| Lilly USA, LLC | $246.50 | 2019-2021 | |
| Pfizer INC. | $222.31 | 2019-2021 | |
| Amarin Pharma, INC. | $216.88 | 2019-2021 | |
| Abbvie INC. | $215.58 | 2019-2021 | |
| Glaxosmithkline, LLC. | $204.56 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.00 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $161.10 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.